COMMUNIQUÉS West-GlobeNewswire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
25/06/2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday [...]
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
25/06/2025
WASHINGTON, June 25, 2025 (GLOBE NEWSWIRE) -- The Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the Cancer Drug Parity Act, bipartisan legislation that would require group and [...]
Main Results of 2025 Annual and Extraordinary General Meeting
25/06/2025
The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. All of [...]
Main Results of 2025 Annual and Extraordinary General Meeting
25/06/2025
REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue [...]
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
25/06/2025
- Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives [...]
Vor Bio Announces $175 Million Private Placement
25/06/2025
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities [...]
Hapbee Issues Clarification of June 24, 2025 Press Release on Q1 2025 Financial Results
25/06/2025
Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62% VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: [...]
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
25/06/2025
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“ Psyence ” or the “ Company ”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, [...]
Hapbee Announces CDN$1.5M Private Placement Led by Company Executive; Announces Appointment of Ahsan Ashraf as Chief Technology Officer
25/06/2025
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company, is pleased to [...]
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
26/06/2025
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE [...]
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
26/06/2025
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation cancer therapies [...]
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
25/06/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of two bondholder meetings held at 17:30 CEST and 19:00 CEST on June 25, [...]
MEME COINS INC., a Controlled Subsidiary of DOGP, to Acquire 2 Billion DOG Tokens from Tipestry
25/06/2025
DOGP Holdings Set to Double to 4.02 Billion DOG MESQUITE, NV, June 25, 2025 (GLOBE NEWSWIRE) -- Denver, CO — MEME COINS INC., a Colorado corporation and controlled subsidiary of Dogecoin Cash Inc. (OTC: DOGP), has [...]
INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent
25/06/2025
SARASOTA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of [...]
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
25/06/2025
Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody [...]
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
25/06/2025
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early [...]
Lifeward Announces Pricing of $2.6 Million Public Oﬀering
25/06/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
Dr. Anosh Ahmed Expands National and International COVID Testing Operations with Renewed Emphasis on Compliance and Fraud Prevention
25/06/2025
Dr. Anosh Ahmed expands COVID testing operations globally with renewed focus on compliance, contract integrity, and fraud prevention Chicago, Illinois, June 25, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed announces the [...]
Novartis completes acquisition of Regulus Therapeutics
25/06/2025
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0. [...]

Pages